Gulba DC - Search Results

1

Ecarin clotting time but not aPTT correlates with PEG-hirudin plasma activity.

Moser M, Ruef J, Peter K, Kohler B, Gulba DC, Paterna N, Nordt T, Kübler W, Bode C. Moser M, et al. Among authors: gulba dc. J Thromb Thrombolysis. 2001 Oct;12(2):165-9. doi: 10.1023/a:1012975522037. J Thromb Thrombolysis. 2001. PMID: 11729368 Clinical Trial.

2

New approaches in plasminogen activator therapy.

Bode C, Gulba D, Huber K, Runge MS. Bode C, et al. Ann Hematol. 1996;73 Suppl 1:S1-7. Ann Hematol. 1996. PMID: 8853111 Review.

3

Thrombolytic therapy in acute myocardial infarction--update 1996.

Huber K, Runge MS, Bode C, Gulba D. Huber K, et al. Ann Hematol. 1996;73 Suppl 1:S29-38. Ann Hematol. 1996. PMID: 8853113 Review.

4

Multicenter dose-finding trial for thrombolysis with urokinase preactivated pro-urokinase (TCL 598) in acute myocardial infarction. German Preactivated Pro-Urokinase Study Group.

Gulba DC, Bode C, Sen S, Topp J, Fischer K, Wolf H, Hecker H. Gulba DC, et al. Cathet Cardiovasc Diagn. 1992 Jul;26(3):177-84. doi: 10.1002/ccd.1810260304. Cathet Cardiovasc Diagn. 1992. PMID: 1617708 Clinical Trial.

5

Thrombolytic agents--an overview.

Gulba DC, Bode C, Runge MS, Huber K. Gulba DC, et al. Ann Hematol. 1996;73 Suppl 1:S9-27. Ann Hematol. 1996. PMID: 8853112 Review.

6

Anticoagulation: the present and future.

Van Aken H, Bode C, Darius H, Diehm C, Encke A, Gulba DC, Haas S, Hacke W, Puhl W, Quante M, Riess H, Scharf R, Schellong S, Schrör T, Schulte KL, Tebbe U. Van Aken H, et al. Among authors: gulba dc. Clin Appl Thromb Hemost. 2001 Jul;7(3):195-204. doi: 10.1177/107602960100700303. Clin Appl Thromb Hemost. 2001. PMID: 11441979 Free article. Review.

7

Restenosis following percutaneous revascularization--the potential role of thrombin and the thrombin receptor.

Stouffer GA, Schmedtje JF, Gulba D, Huber K, Bode C, Aaron J, Runge MS. Stouffer GA, et al. Ann Hematol. 1996;73 Suppl 1:S39-41. Ann Hematol. 1996. PMID: 8853114 Review.

8

Plasmin activation system in restenosis: role in pathogenesis and clinical prediction?

Christ G, Kostner K, Zehetgruber M, Binder BR, Gulba D, Huber K. Christ G, et al. J Thromb Thrombolysis. 1999 Jun;7(3):277-85. doi: 10.1023/a:1008983110941. J Thromb Thrombolysis. 1999. PMID: 10375389 Review.

9

Argatroban for elective percutaneous coronary intervention: the ARG-E04 multi-center study.

Rössig L, Genth-Zotz S, Rau M, Heyndrickx GR, Schneider T, Gulba DC, Desaga M, Buerke M, Harder S, Zeiher AM; ARG-E04 study group. Rössig L, et al. Among authors: gulba dc. Int J Cardiol. 2011 Apr 14;148(2):214-9. doi: 10.1016/j.ijcard.2010.02.044. Epub 2010 Mar 11. Int J Cardiol. 2011. PMID: 20226548 Clinical Trial.

10

[Incidence of residual thrombi following successful thrombolytic therapy in acute myocardial infarct and their significance for the rate of early re-occlusion. A report of a multicenter dose-finding study for thrombolytic therapy with urokinase preactivated natural prourokinase (TCL 598)].

Gulba DC, Bode C, Topp J, Höpp HW, Westhoff-Bleck M, Rafflenbeul W, Lichtlen PR. Gulba DC, et al. Z Kardiol. 1990 Apr;79(4):279-85. Z Kardiol. 1990. PMID: 2113330 Clinical Trial. German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

115 results

Search Page

Filters